BioAge Labs, Inc. (NASDAQ:BIOA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) have received an average recommendation of “Moderate Buy” from the four analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $45.00.

BIOA has been the topic of a number of recent analyst reports. Morgan Stanley set a $23.00 price objective on shares of BioAge Labs in a research report on Wednesday, February 4th. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, January 27th. Citigroup increased their price target on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Oppenheimer began coverage on BioAge Labs in a report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price objective for the company. Finally, Piper Sandler assumed coverage on BioAge Labs in a research report on Tuesday, January 27th. They issued an “overweight” rating on the stock.

Insider Activity

In other news, insider Paul D. Rubin sold 7,433 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $18.75, for a total transaction of $139,368.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kristen Fortney sold 233,107 shares of the company’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the completion of the transaction, the chief executive officer owned 976,949 shares in the company, valued at approximately $17,702,315.88. The trade was a 19.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 267,540 shares of company stock valued at $4,895,168. 20.82% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BIOA. CWM LLC increased its holdings in BioAge Labs by 39.9% during the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after purchasing an additional 1,053 shares during the period. Russell Investments Group Ltd. bought a new position in shares of BioAge Labs during the 3rd quarter worth $27,000. China Universal Asset Management Co. Ltd. bought a new position in shares of BioAge Labs during the 4th quarter worth $77,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of BioAge Labs during the second quarter valued at $27,000. Finally, Nisa Investment Advisors LLC increased its stake in shares of BioAge Labs by 4,219.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock valued at $135,000 after buying an additional 10,000 shares during the period.

BioAge Labs Trading Down 8.3%

Shares of BIOA opened at $19.30 on Friday. The company’s fifty day simple moving average is $20.28 and its 200-day simple moving average is $12.60. The company has a market cap of $691.91 million, a P/E ratio of -12.70 and a beta of 1.22. BioAge Labs has a twelve month low of $2.88 and a twelve month high of $24.00.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.